Affymax, Inc. (OTCPK: AFFY)
Health Care · Biotechnology · US
$0.00
+6.67% today · +100.0% 1Y
Affymax, Inc. (OTCPK: AFFY) operates in the Biotechnology industry within the Health Care sector. The company is valued at $119.18K and employs 2 people.
Over the last twelve months the share price has gained 100.0%, trading between 0.00 and 0.00.
Tweenvest scores Affymax, Inc. across four factors: quality 24/100, value 51/100. Its strongest factor is value.
AFFY price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $119.18K
- Revenue (TTM)
- $42.00K
- P/E
- 0.02
- EPS
- 0.08
- Dividend yield
- —
- Beta (5Y)
- 7.43
- 52-week high
- $0.00
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 74.49M
- Employees
- 2
- Next earnings
- —
About Affymax, Inc.
Affymax, Inc. presently lacks any substantial operational activities. In its earlier history, the firm concentrated on the creation of pharmaceutical agents designed to improve therapies for severe and frequently fatal health issues across the United States. Established in 2001, its corporate base is situated in New York, New York.
- ISIN
- US00826A1097
- Founded
- 2001
- Listed since
- Dec 15, 2006
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $262.90 | -1.09% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $440.34 | -0.43% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.09 | -0.46% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $547.29 | -1.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $814.79 | -2.25% |
| argenx SEENXTBR: ARGX | $64.17B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $149.66 | -5.77% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.